Growth Metrics

Idexx Laboratories (IDXX) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Idexx Laboratories (IDXX) over the last 17 years, with Q3 2025 value amounting to $274.6 million.

  • Idexx Laboratories' Income from Continuing Operations rose 1793.89% to $274.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 1860.76%. This contributed to the annual value of $887.9 million for FY2024, which is 506.78% up from last year.
  • According to the latest figures from Q3 2025, Idexx Laboratories' Income from Continuing Operations is $274.6 million, which was up 1793.89% from $294.0 million recorded in Q2 2025.
  • Idexx Laboratories' 5-year Income from Continuing Operations high stood at $294.0 million for Q2 2025, and its period low was $132.0 million during Q2 2022.
  • Moreover, its 5-year median value for Income from Continuing Operations was $204.3 million (2021), whereas its average is $208.8 million.
  • In the last 5 years, Idexx Laboratories' Income from Continuing Operations soared by 8263.57% in 2021 and then plummeted by 3485.93% in 2022.
  • Quarter analysis of 5 years shows Idexx Laboratories' Income from Continuing Operations stood at $162.8 million in 2021, then grew by 5.8% to $172.2 million in 2022, then rose by 12.96% to $194.5 million in 2023, then grew by 11.12% to $216.1 million in 2024, then grew by 27.05% to $274.6 million in 2025.
  • Its Income from Continuing Operations was $274.6 million in Q3 2025, compared to $294.0 million in Q2 2025 and $242.7 million in Q1 2025.